value of hs-cTnT to rule out myocardial infarction in chest pain patients in the emergency department.
the ECG had a final diagnosis of myocardial infarction, of which 13 patients had hs-cTnT <5 ng/l within 3 h after the onset of chest pain, and 11 of the 13 patients were found to have hs-cTnT elevation after 3 h (2). Therefore, we presumed that the negative predictive value for myocardial infarction with undetectable hs-cTnT within 3 h after the onset of chest pain was much lower than what the original study reported. Given a lot of patients with chest pain are going to the emergency department within 3 h (4), the low negative predictive value of hs-cTnT might render a number of missed diagnoses. As a consequence, we considered that the conclusion of the original study was too arbitrary, which might inadvertently mislead clinicians into making mistakes.
Besides, a diurnal hs-cTnT rhythm was detected by Klinkenberg et al. (5) . The diurnal variation of hscTnT was characterized by peak concentrations during the morning hours (by 08:30 h), gradually decreasing values during the daytime (until 20:30 h), and rising concentrations during the nighttime (until 08:30 h the next day) (5), which might also affect the accuracy of hs-cTnT on predicting myocardial infarction.
In conclusion, we think the utilization of hs-cTnT should be combined with the duration of the events and the diurnal hs-cTnT rhythm. First, this was an observational trial, and no patients were actually discharged by virtue of their findings. In fact, at least 21% were hospitalized using Please note: Dr. Cullen has received grant funding from Roche, Abbott Diagnostics, and Alere; and has received speaker's fees or honoraria from Abbott Diagnostics, Beckman Coulter, and Alere. Dr. Than has received grant funding, consulting fees, or honoraria from Roche, Beckman Coulter, Abbott Diagnostics, and Alere. Dr. Peacock has received research grants from Abbott, Alere, Banyan, Cardiorentis, Portola, Roche, and The Medicines Company; has received consultancy fees from BG Medicine, Beckman, Boehringer-Ingelheim Instrument Labs, The Medicines Company, Alere, Cardiorentis, and Jannsen; and he has ownership interests in Comprehensive Research Associates LLC and Emergencies in Medicine LLC. Firstly, we do agree that our findings need to be validated in other settings than a university hospital, with a different diversity of ethnicity, socioeconomic status, and prevalence of cardiovascular disease.
R E F E R E N C E
All patients who were included in our study had chest pain, an electrocardiogram (ECG) recorded, and at least 1 troponin level measured (1). To our knowledge, troponins are not used for any other reasons than to confirm or to exclude myocardial ischemia. In addition, all patients had a clinical assessment made, which we believe is common practice. Occasionally, patients were assessed clinically after the troponin level was available, and an explanation for the chest pain other than a myocardial infarction (MI) would lead to a discharge home. We believe that this is in line with how patients with chest pain are assessed in most emergency departments (ED).
Seventy-seven percent of admitted patients went home the same or the next day. Naturally, diagnoses such as pneumonia, pulmonary embolism, or atrial fibrillation may have necessitated longer hospital stays. Our primary aim was not to investigate risk mitigation in admitted versus discharged patients.
We believe that exercise tests, stress echocardiograms, or coronary angiograms by themselves have no impact on prognosis. We do acknowledge that there may have been patients discharged who may have had a second troponin >14 ng/l if measured.
However, the risk of all-cause mortality was not higher in patients discharged versus admitted, and there were only 2 cardiovascular deaths within 12 months in 8,907 patients with troponins <5 ng/l, which indicates an excellent long-term prognosis.
In a random sample of 100 patients, the mean time to measurement of troponins was 2.5 h. Thus, most patients had their first troponin level evaluated J A C C V O L . 6 4 , N O . 6 , 2 0 1 4 Letters A U G U S T 1 2 , 2 0 1 4 : 6 2 8 -3 4
